Nonavalent vaccine against HPV - the end of discussions about its efficacy

Abstract

Nonavalent vaccine against HPV 6/11/16/18/31/33/45/52/58 can increase the protective potential achieved by the quadrivalent vaccine from 70% to 90% for cervical cancer and furthermore it covers 85-95% of HPV-related carcinomas in the areas of the vulva, vagina and anus. The effects and immunogenicity against HPV6/11/16/18 are the same as with quadrivalent vaccine.

Its efficacy against lesions associated with HPV 31/33/45/52/58 is 97%.

Keywords

• HPV infection
• prevention
• nonavalent vaccine
• cervical cancer
• genital warts